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REVIEW ARTICLE

ACUTE RESPIRATORY DISTRESS SYNDROME- A CONCISE CLINICAL
REVIEW
Erfan Hussain*, Fahad Hamid**
ABSTRACT:
Acute Respiratory Distress Syndrome (ARDS) is a challenging and deadly disease faced by
critical care specialists. The literature concerning ARDS has been increasing for the last 12
years and there are now many options available to treat this disease. However, not all of these
options work and some may even be harmful to patients. The purpose of this paper is to provide
the reader with a review of the new criteria for ARDS definition and to discuss the pros and cons
of the various treatment options now available.
Introduction:
ARDS is a complex clinical syndrome that represents a consistent recognizable pattern resulting
from a large variety of both infectious and noninfectious etiologies. Over the last 12 years there
has been an increasing amount of research done concerning ARDS, from establishing better
evidence based studies for treatment to improving the definition. The main objectives for this
review will be to describe the New Berlin Criteria for ARDS as well as briefly describing the pros
and cons of the various treatment options available. For more detailed reviews of etiology and
pathogenesis, the interested reader is referred to the bibliography for further reading1,2.
Epidemiology:
In general ARDS occurs in approximately 5% of in-hospital cases on mechanical ventilation with
a clinical burden of approximately 200,000 cases per year in the U.S. However, this number
varies from country to country. Using the American-European 1994 Consensus Conference
statement (AECC) definition ARDS occurs as follows: 64.2-78.9 cases/100,000 person years in
the U.S, 7.2 cases/100,000 person years in Spain, 34 cases/100,000 person years in New
Zealand/Australia, and 17cases/100,000 person years in Northern Europe3. The explanation for
this disparate incidence between different regions of the world remains unclear. This difference
may partially be explained by variations in healthcare delivery systems and demographics3.
Current trends would suggest that if there is no effective preventative treatment developed for
ARDS, incidence rates may be expected to rise to by 50% by 2030 in the U.S. alone
representing approximately 330,000 cases/year4.
Mortality:
In the U.S. ARDS/ALI (Acute Lung Injury) results in approximately 74,000 deaths per year. To
place this number in perspective, the ARDS mortality rate exceeds the mortality rates of other
diseases such as breast cancer, HIV, and asthma in the U.S.5. Risk factors for increased
mortality in ARDS are: increased dead space fraction (greater than 0.60), hypoxemia
(PAO2/FIO2 under 100), pulmonary vascular alterations, poor lung compliance, shock, liver
dysfunction, acute kidney injury, age over 60, and increased severity of illness scores1. Only a
relative minority of ARDS patients die of refractory hypoxemia (13%-15%) 3.
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The mortality rate of ARDS has been decreasing. Using the ARDS Network trials 60 day
mortality endpoint, ARDS has declined from 36% (1996-1997) to 26% (2004-2005), with the
most recent ARDS Net trial showing a mortality of 22% despite higher incidences of shock and
higher severity of illness scores 1. This decrease in ARDS mortality has been ascribed to better Page | 2
compliance and increased usage of the ARDS Net protocol. However there appears to be a
plateauing effect of this decreased mortality trend thus necessitating the discovery and testing
of new treatment options and preventive measures.
Definition:
The need for a stable and reproducible definition for ARDS is obvious when designing and
implementing single center or multi center trials. The description of the syndrome of ARDS is
generally credited to the article by Ashbaugh and Petty published in 1967. However, it is likely
that the disease was described earlier in the medical literature with Laennec describing a fatal
case of idiopathic pulmonary edema, published in 1821. During the twentieth century diseases
described as “wet lung, Da Nang lung and shock lung ” were all various names describing what
is now termed ARDS 3.
In 1988 Murray et al attempted to expand the definition of ARDS creating the Lung Injury Score
(LIS) 6. The LIS graded ARDS severity across 4 main domains. These are: Number of
quadrants involved in the chest x-ray, P/F ratio, PEEP, and lung compliance. Each domain is
scored between 0-4 (Table I). However this score was found to be too complicated to practically
implement in the clinical setting. In 1994 the AECC definition was created 7. This definition
remained the definition for ARDS until the recently proposed Berlin Criteria.
The 1994 AECC definition for ARDS is as follows: 1) Acute in onset, 2) bilateral infiltrates on a
frontal chest x-ray, 3) No clinical or hemodynamic (wedge greater than 18) signs of left atrial
hypertension and finally 4) a PaO2/FIO2 ratio of less than 200. In addition, a new category of
Acute Lung Injury (ALI), defined as points 1-3 with a PaO2/FIO2 ratio of 200-300 was created.
The need for the new definition of ALI was felt to be necessary in order to incorporate the range
of clinical severity seen with ARDS. However there were several issues identified with the
AECC 1994 definition. These are: 1) No clear cut definition of “acute”, 2) the chest x-ray
definition has been found to have moderate to poor inter-observer reliability, 3) The PaO2/FIO2
ratio is not constant over a range of FIO2 and PEEP, 4) subsequent to the AECC definition
elevated wedge pressures have been demonstrated in patients with ARDS and no congestive
heart failure. This could be due to transmission of positive pressure from the ventilator and
aggressive fluid resuscitation. And finally 5) there is evidence that the AECC criteria can result
in under identification of ALI/ARDS 8. Due to these limitations an international panel was
created, tasked with refining and adjusting the AECC criteria. This resulted in the current
definition of ARDS referred to as the Berlin Criteria (Table II).
The Berlin Criteria included several changes from the AECC criteria and initially minute
ventilation (as a surrogate for dead space) and lung compliance were added. However, in a
subsequent validation study of 4188 patients with ARDS from 4 multicenter datasets and 269
patients from 3 single center datasets, it was found that the criteria of lung compliance and

minute ventilation did not add to the predictive power of the definition and therefore these were
removed from the final definition set 9
The final definition of the Berlin Criteria is as follows: 1) Timing: defined as within one week of
worsening respiratory symptoms or after a defined insult known to cause ARDS,
2) Chest x-ray: bilateral opacities not fully caused by effusions, nodules, or lobar/ lung collapse,
3) Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid over load. Page | 3
Objective assessment of hydrostatic edema if no risk factors of ARDS is found
(echocardiography). Of note PCWP pressure was removed and finally 4) the criteria of ALI was
removed and a minimum requirement of PEEP (greater than or equal to 5cmH 2O) was added
and three categories of severity were created. These are: P/F ratio of 200-300 mmHg (mild),
100-200 mmHg (moderate), and finally less than or equal to 100 mmHg (severe).
Overall, the Berlin Criteria performed better than the AECC criteria for mortality prediction
(p<.001). However, the Berlin Criteria Area under the Receiver Operating Curve (AUC) was only
marginally better than the AECC AUC (0.577 versus 0.536), though this did reach statistical
significance as described above. With better definitions for acuity, chest x-ray findings, removal
of the PCWP, addition of a minimum PEEP value and the deletion of the ALI designation the
Berlin Criteria attempted to compensate for the known deficiencies of the AECC Criteria.
Recently, using diffuse alveolar damage (DAD) as the pathological lesion of ARDS, the
sensitivity and specificity of the Berlin Criteria was compared to autopsy findings of ARDS. The
Berlin Criteria was found to perform well with autopsy findings of both mild and severe ARDS 10.
Further clinical studies are needed to better define the sensitivity and specificity of the Berlin
Criteria for detecting ARDS and its clinical severity subgroups. However, at present, the Berlin
Criteria is the new definition for ARDS.
Treatment:
Over the last twelve years there has been significant improvement in our understanding of what
works, what may work and what doesn’t work for the treatment of ARDS. This present section
will provide an update review of these therapies.
ARDS Net Protocol:
Published in the New England Journal of Medicine in 2000, the ARDS Network study of using
lower tidal volumes to ventilate patients with ARDS represented a major advance in the
treatment of ARDS 11. Presently the ARDS Net lower tidal volume strategy represents the
standard of care for the treatment of ARDS receiving a level 1A recommendation in the most
recent Surviving Sepsis Campaign Guidelines 12. The ARDS net protocol built on a growing
body of animal studies of ARDS 13. These studies demonstrated that cyclic volume changes
causing alveolar opening and closing (atelectrauma) as well as alveolar volume over distension
in reaction to mechanically delivered tidal volumes (volutrauma) can cause ARDS de novo as
well as worsen existing ARDS. Unfortunately, adherences to using the ARDS Net lower tidal
volume protocol remain less than optimal. A recent study evaluating the effect of using the lower
tidal volume strategy on two year ARDS mortality found only a 41% compliance rate of using a
low tidal volume strategy. Adherence to the ventilator strategies of the ARDS Net protocol
resulted in a 3% decrease in mortality over 2 years for each element adhered to 14. For a

description of the ARDS Net protocol the interested reader is referred to the ARDS Net web
address at www.ardsnet.org/system/files/Ventilator%20Protocol%20Card.pdf
Conclusion: At present the use of the ARDS Net protocol remains one of the definitive
treatments for ARDS.
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Fluid Strategy for ARDS
Starling’s equation offers a physiological basis for fluid restriction in ARDS.
The equation is defined as follows:
where Kf is the filtration coefficient, Pc capillary hydrostatic pressure, Pi Interstitial hydrostatic
pressure, reflection coefficient, c Capillary oncotic pressure and i is the Interstitial oncotic
pressure.
Based on this equation alteration in the reflection coefficient is one of the issues reflecting
capillary leak and non-cardiogenic edema generation. Animal models of ARDS have suggested
that a lower Pc results in a decrease in edema generation 15,16. Two major human trials
evaluating a fluid restrictive strategy for ARDS have been conducted of which the ARDS Net
Fluids and Catheter Therapy Trial (FACTT trial) remains the largest multicenter trial to date 17,18
Both of these studies found no difference in the 28 day and 60 day mortalities respectively. Both
studies found a significant increase in ventilator free days and less days spent in the ICU.
One of the possible untoward side effects of a fluid restrictive strategy and diuresis for ARDS is
the potential for developing Acute Kidney Injury (AKI). A post hoc evaluation of the FACTT trial
for AKI revealed that the occurrence of AKI was increased in the fluid liberal arm of the trial as
well as a decreased survival rate in this group. Another post hoc study found that of the 306
patients in the FACTT trial that developed AKI within the first 48 hours of enrollment, those in
positive fluid balance had a greater mortality. This study also found that a higher diuretic dose
after AKI correlated with increased survival 18.
In addition in the same patient set as the FACTT study, it was demonstrated that the use of a
Pulmonary Artery Catheter (PAC) was not necessary to treat ARDS when compared to the use
of a CVP catheter 19.
Conclusion: At present a fluid restrictive strategy does not improve mortality in ARDS. However
a fluid restrictive strategy can result in greater ventilator free days and fewer days spent in the
ICU without compromising perfusion of other vital organs. The need of a liberal fluid strategy in
the initial stages of ARDS with shock needs to continue balanced against a fluid restrictive
strategy once the initial fluid resuscitation is completed. There is no role for the routine use of a
PAC in the treatment of ARDS.
Corticosteroids and ARDS:
Pathologically ARDS goes through three overlapping phases of exudation, proliferation and
fibrosis. The initial phase of ARDS is marked by intense inflammation with neutrophil influx and
increased proinflammatory cytokine release. Thus, on a theoretical basis the application of
corticosteroids should have a salutatory effect in decreasing this proinflammatory milieu and
improve outcome in ARDS. Unfortunately clinical trials have had mixed results. In evaluating the
role of corticosteroids for ARDS it is important to know the etiology of the ARDS under study.
For example corticosteroids remain as suggested therapy for a multitude of non-infectious
causes of ARDS such as acute interstitial pneumonia, hypersensitive pneumonitis, sarcoidosis,
fat embolism, and post bone marrow transplant alveolar hemorrhage syndrome. However when

corticosteroid use has been studied in large scale clinical trials, incorporating all comers with
ARDS, corticosteroids have not been shown to improve mortality. The ARDS net phase III trial
is the largest of these clinical trials 20. Patients with unresolved ARDS greater than day 7 were
enrolled. The study found the following: 1) no survival advantage using steroids, and 2)
subgroup analysis showed increased mortality and neuromuscular weakness in the patients that
received their initial dose of low dose methylprednisolone (0.5-1mg/kg/day) beyond day 14. Page | 5
Recently a study conducted in 55 patients who received early methylprednisolone for ARDS had
statistically significant shorter duration of mechanical ventilation, an improvement in the LIS, and
lower intensive care unit mortality when compared to the control group. Also lower levels of
interleukin-6 and increased levels of protein c were found on days 3 and 7 in the treatment
arm21.
Conclusion: At present the routine use of corticosteroids for the treatment of ARDS cannot be
recommended. The use of corticosteroids in early severe ARDS and in fibrosing ARDS (before
day 14) may be considered but the literature is not strong enough yet to make a firm
recommendation.
PEEP and ARDS:
To date there have been 3 large scale clinical trials evaluating different PEEP strategies in
ARDS. The Assessment of Low Tidal Volume and Elevated End-Expiratory Volume to Obviate
Lung Injury trial (ALVEOLI) compared high PEEP to low PEEP strategy for ALI. The Expiratory
Pressure Study Group (EXPRESS) trial studied the effect of low PEEP to a recruitment PEEP
strategy for creating the high PEEP group in patients with ALI. Finally the Lung Open Ventilation
Study (LOV) used a PEEP level (higher or lower) based upon an oxygenation scale. Recently
these 3 studies were analyzed in a meta-analysis that concluded that a higher PEEP strategy
improved survival in the subset of patients who had ARDS. In contrast the use of high PEEP in
patients with ALI without ARDS conferred no survival benefit and may actually harm patients
with ALI 22.
Conclusion: At present a high PEEP strategy should be considered for use in patients with
ARDS. High PEEP strategies should be avoided in patients with ALI or with mild ARDS as
defined in the Berlin Criteria.
Prone Positioning:
From the earlier studies done of CT scans of the chest in patients with ARDS, it became
apparent that though the disease may appear diffusely homogenous on chest x-ray on CT scan
there was a gravity dependent distribution of ARDS. As patients in an ICU lie supine this
distribution of ARDS was seen in the dorsal portions of the lung. Prone positioning a patient
involves placing the patient on their stomach rather than back. Theoretically this should result in
better gravity dependent perfusion of the relatively “normal” ventral lung and better ventilation of
the dorsal lung.
However, until recently studies using prone positioning as a therapy for ARDS have not
demonstrated any survival benefit. One large study actually reported an increased incidence of
ET-tube displacement, and pressure sore development using prone positioning 23. Recently a
multi-center prospective trial using prone positioning for patients with severe ARDS (defined as
a PAO2/FIO2 ratio of less than 150 mmHg) demonstrated an almost 50 % reduction in 28 day
mortality (Supine 32.8% mortality versus 16% in the prone group)24.

Conclusion: At present prone positioning is not recommended for routine use in ARDS. It should
be considered rescue therapy for patients with a PAO2/FIO2 ratio of less than 150 mmHg 24,25.
Using prone positioning requires local expertise (both nursing and physician) to properly care for
a pronated patient. Given the general lack of availability and resource requirements of other
“heroic” maneuvers such as ECMO, high frequency oscillation, and nitric oxide in Pakistan,
prone positioning may represent the only simple and readily available rescue maneuver that can Page | 6
realistically be performed here. This technique of prone positioning should be considered for
use especially with the recent New England Journal of Medicine article demonstrating a
significant survival benefit for patients with severe ARDS
Extra-Corporeal Membrane Oxygenation (ECMO)
First studied in the 1970s, ECMO use for ARDS was viewed as non-beneficial. However, during
the H1N1 outbreak in 2009 groups in Australia and New Zealand reported good outcomes using
ECMO to treat ARDS from H1N1 26. Of the 68 patients who received ECMO there was a 75%
survival rate. Subsequently a prospective trial was done in the UK called CESAR (conventional
ventilator support versus ECMO for severe adult respiratory failure). This study found that at 6
months the mortality and disability of the 90 patients that received ECMO was better than the
control arm of usual ventilation (37% versus 53%, p=0.03). However this study has been
criticized for 2 main reasons. 1) Twenty two patients randomized to the ECMO arm did not
receive ECMO therapy, and 2) there was no specification as to what type of ventilator treatment
(i.e. ARDS Net protocol) the control arm should receive 27.
Newer devices are being developed such as veno-venous ECMO, pumpless interventional lung
assist (iLA) and ECMO-R (extra corporeal carbon dioxide removal) 28. These newer devices
may play a role in the future treatment of severe early ARDS. At present though, with standard
ECMO use there is still a high risk of bleeding (54%) and a 9% chance of intracranial
hemorrhage 3.
Conclusion: In the future Extra-Corporeal Oxygenators and CO2 removal devices may help in
the treatment of severe ARDS. At present its role in the treatment of ARDS remains
investigational.
IV Beta Agonists:
The use of beta agonists in the treatment of ARDS makes some theoretical sense as beta
agonists have been shown to be helpful in lung water clearance. However a recent multi-center
trial called the Beta Agonists in Lung Injury Trial (BALTI 2) study demonstrated that IV beta
agonist use in ARDS was associated with poor patient tolerance, was unlikely to be beneficial,
and may actually pose some harm to the patient 29.
Conclusion: IV beta agonists should not be used as part of the treatment for ARDS.
High Frequency Oscillation Ventilation (HFOV)
Theoretically the use of HFOV should be useful in ARDS. If 6cc/kg works then using even lower
tidal volumes at 6cc total/per breath should further limit lung trauma with mechanical ventilation.
Unfortunately this has not been borne out in human trials. The Oscillation for Acute Respiratory
Distress Syndrome Treated Early (OSCILLATE) trial and the Oscillation in ARDS (OSCAR) trial
results were recently published 30,31. The OSCILLATE trial found that the application of HFOV
resulted in greater deaths in the treatment arm and the study was terminated early. The OSCAR
trial found no statistical significance in mortality between the treatment and control groups. In

both the OSCAR and OSCILLATE trials patients on HFOV had higher usage of sedation and
neuromuscular paralysis then the control patients.
Conclusion: At present the use of HFOV cannot be recommended for routine use in ARDS. At
best, HFOV may be considered as a rescue maneuver for patients with severe ARDS.
Neuromuscular Blockade Agents (NMBA):
NMBA use in ICU patients can result in prolonged paralysis from critical illness polyneuropathy, Page | 7
and critical illness myopathy. As awareness of this side effect of NMBA grew there was a
movement away from their routine use in ARDS. The recent publication of the ACURASYS
Study has started to change the prevalent opinion of avoiding NMBA use in patients with ARDS
This study used cisatracurium besylate for 48 hours in the initial treatment of ARDS versus
placebo 32. The study found that the use of cisatracurium improved the adjusted 90 day survival
for patients with severe ARDS (P/F ratio less than 120). The study found no difference in the
development of ICU paresis between the two groups.
Conclusion: Presently the routine use of NMBAs for the treatment of ARDS cannot be
recommended. The use of NMBA in patients with severe early ARDS (P/F ratio less than 120)
may be considered.
Inhalation Therapies:
Nitric Oxide (NO): Nitric Oxide is a gas that when inhaled results in a decrease in pulmonary
vascular pressures and improves V/Q matching. A recent Cochrane analysis of 14 trials using
NO for the treatment of ARDS found no survival benefit, no change in ventilator free days and
no change in ICU or hospital length of stay 33. There is a temporary reduction in FIO2
requirements. In addition an increased incidence of renal dysfunction was also found in the
Cochrane analysis.
Iloprost: As an inhaled prostanoid, Iloprost’s physiological results are similar to NO. Recently a
published study demonstrated that in 20 patients with ARDS and pulmonary hypertension
(defined either by ECHO or PAC) the use of Iloprost resulted in a statistically significant
improvement in PaO2 34.
Conclusion: Though not associated with improvement in mortality, the use of inhaled pulmonary
vasodilators may be considered for rescue therapy to then allow other aspects of ARDS care to
be implemented. However, at present these agents cannot be recommended for routine use in
ARDS treatment.
Conclusion: Though there have been improvements in the management and mortality of
ARDS, this disease still remains a challenging and deadly syndrome faced by critical care
specialists. Adherence to the ARDS Net protocol remains the mainstay of therapy. Ongoing
studies may help to better clarify new treatment options as well as improve our understanding of
the exact role that existing therapies may have in the future. At present given the resource
limitations of many of the above described therapies here in Pakistan, consideration should be
given to the creation of prone positioning protocols to treat patients with severe ARDS. At
present the Berlin Criteria and its severity scale, are the criteria that should be used to define
ARDS.
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Table I: Lung Injury Score
0
Chest X-ray: None
number
of
quadrants
involved
PAO2/FIO2
>300
Ratio
PEEP cmH2O <5
Lung
>80
Compliance
ml/cm H2O
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1
1

2
2

3
3

4
4

225-299

175-224

100-174

< 100

6-8
60-79

9-11
40-59

12-14
20-39

>15
<19

Table II: AECC and Berlin Criteria
AECC
Timing

Chest X-ray

Origin of Edema

Oxygenation
PAO2/FIO2 Ratio
Mild
Moderate
Severe

Berlin Criteria

Acute Onset

Within 1 week of known clinical
insult or worsening Respiratory
Symptoms
Bilateral Infiltrates
Bilateral
opacities:
Not
explained
by
effusions
collapse, or nodules
Pulmonary Artery Wedge Not of cardiac origin or fluid
pressure <18 mmHg or no overload.
clinical signs of Left Atrial Objective measurement in the
Hypertension
absence of risk factors

PAO2/FIO2 ratio of 200-300 200-300 with PEEP or CPAP >
mmHg
5 cmH2O
Acute Lung Injury (ALI)
100-200 with PEEP
> 5cmH2O
< 200mmHg (ARDS)
< 100 with PEEP > 5 cmH2O
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